BioSpace News Archive

Policy

Novo Nordisk A/S: Ozempic (Semaglutide) Approved in the EU for the Treatment of Type 2 Diabetes

The marketing authorisation applies to all 28 European Union member states.

February 9, 2018

·

2 min read

Biotech Beach

Crown Biosciences: Enhanced MuScreen Platform Revolutionizes Preclinical Development of Immunotherapeutics

Immunotherapies, alone or in combination with other drugs, treat cancer by modulating the immune system to elicit native antitumor immune responses.

February 9, 2018

·

2 min read

Drug Development

Catalyst Biosciences Announces Positive Top-Line Data from Phase I/II Study of Subcutaneous CB 2679d/ISU304 in Individuals With Hemophilia B

Results from the trial showed a continuous linear increase in Factor IX activity levels following daily dosing of CB 2679d for six days.

February 9, 2018

·

6 min read

Deals

CAS Group Supports Improved Vaxart Merger and Enters Into Agreement With Aviragen

The Company previously announced that the special meeting of Aviragen stockholders, originally scheduled for February 6, 2018.

February 9, 2018

·

4 min read

Genetown

Oncobindi Therapeutics: Precision Oncology Assets: Fast-Track Development from lead Candidate to Clinic

We are entering an era of rapidly evolving transformation in cancer treatment as it relates to drug development, and a shifting paradigm of standardized health care in which detailed genetic and molecular information regarding a patient’s cancer is being used for personalized precision treatments.

February 9, 2018

·

1 min read

Business

Peli BioThermal Joins Poseidon Sea Freight Program as Founding Member

Peli BioThermal, the global name in temperature controlled packaging, has announced their founding membership in Poseidon.

February 9, 2018

·

1 min read

Pharm Country

PAVmed Announces Completion of Offer to Exercise Series W Warrants at a Temporarily Reduced Price

PAVmed today announced the completion of its previously announced offer to exercise its publicly-traded warrants (the “Series W Warrants”) at a temporarily reduced exercise price of $2.00 per share.

February 9, 2018

·

4 min read

Business

Syneos Health Names Lisa van Capelle Chief Human Resources Officer

Syneos Health has announced the appointment of Lisa van Capelle as Chief Human Resources Officer.

February 9, 2018

·

2 min read

Zucara Therapeutics Receives Funding to Advance Lead Drug Candidate

Zucara recently defined its lead drug candidate, ZT-01, and this support will enable Zucara to conduct critical validation work and further advance ZT-01 through preclinical testing.

February 9, 2018

·

1 min read

BioAmber Announces Registered Direct Offering; Termination of Underwriting Agreement for Previously-Announced Public Offering

The Series A warrants have an exercise price of US$0.15 and a term of six months, exercisable upon the date of issuance.

February 9, 2018

·

8 min read